WO2005069900A3 - Npc1l1 (npc3) and methods of identifying ligands thereof - Google Patents

Npc1l1 (npc3) and methods of identifying ligands thereof Download PDF

Info

Publication number
WO2005069900A3
WO2005069900A3 PCT/US2005/001469 US2005001469W WO2005069900A3 WO 2005069900 A3 WO2005069900 A3 WO 2005069900A3 US 2005001469 W US2005001469 W US 2005001469W WO 2005069900 A3 WO2005069900 A3 WO 2005069900A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
bind
npc3
npc1l1
identifying ligands
Prior art date
Application number
PCT/US2005/001469
Other languages
French (fr)
Other versions
WO2005069900B1 (en
WO2005069900A2 (en
Inventor
Margarita Garcia-Calvo
Original Assignee
Merck & Co Inc
Margarita Garcia-Calvo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc, Margarita Garcia-Calvo filed Critical Merck & Co Inc
Priority to JP2006549676A priority Critical patent/JP4590417B2/en
Priority to EP05711542A priority patent/EP1723414A4/en
Priority to MXPA06008124A priority patent/MXPA06008124A/en
Priority to CA2553769A priority patent/CA2553769C/en
Priority to US10/586,310 priority patent/US7901893B2/en
Publication of WO2005069900A2 publication Critical patent/WO2005069900A2/en
Publication of WO2005069900A3 publication Critical patent/WO2005069900A3/en
Publication of WO2005069900B1 publication Critical patent/WO2005069900B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/60—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving cholesterol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5076—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving cell organelles, e.g. Golgi complex, endoplasmic reticulum
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Abstract

The present invention provides human, rat and mouse NPCIL1 polypeptides and polynucleotides encoding the polypeptides. Methods for detecting ligands which bind to NPClL1 and block intestinal cholesterol absorption are provided. Also included is a method of identifying ligands which bind to NPCILI using membranes derived from brush border membrane preparations. Compounds that bind to NPCILI can be used for inhibiting intestinal cholesterol absorption in a subject.
PCT/US2005/001469 2004-01-16 2005-01-14 Npc1l1 (npc3) and methods of identifying ligands thereof WO2005069900A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2006549676A JP4590417B2 (en) 2004-01-16 2005-01-14 NPC1L1 (NPC3) and method for identifying this ligand
EP05711542A EP1723414A4 (en) 2004-01-16 2005-01-14 Npc1l1 (npc3) and methods of identifying ligands thereof
MXPA06008124A MXPA06008124A (en) 2004-01-16 2005-01-14 Npc1l1 (npc3) and methods of identifying ligands thereof.
CA2553769A CA2553769C (en) 2004-01-16 2005-01-14 Npc1l1 (npc3) and methods of identifying ligands thereof
US10/586,310 US7901893B2 (en) 2004-01-16 2005-01-14 NPC1L1 (NPC3) and methods of identifying ligands thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53734104P 2004-01-16 2004-01-16
US60/537,341 2004-01-16

Publications (3)

Publication Number Publication Date
WO2005069900A2 WO2005069900A2 (en) 2005-08-04
WO2005069900A3 true WO2005069900A3 (en) 2006-06-08
WO2005069900B1 WO2005069900B1 (en) 2006-08-03

Family

ID=34807095

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/001469 WO2005069900A2 (en) 2004-01-16 2005-01-14 Npc1l1 (npc3) and methods of identifying ligands thereof

Country Status (6)

Country Link
US (1) US7901893B2 (en)
EP (1) EP1723414A4 (en)
JP (1) JP4590417B2 (en)
CA (1) CA2553769C (en)
MX (1) MXPA06008124A (en)
WO (1) WO2005069900A2 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0215579D0 (en) 2002-07-05 2002-08-14 Astrazeneca Ab Chemical compounds
US20040132058A1 (en) * 2002-07-19 2004-07-08 Schering Corporation NPC1L1 (NPC3) and methods of use thereof
US7135556B2 (en) 2002-07-19 2006-11-14 Schering Corporation NPC1L1 (NPC3) and methods of use thereof
CN100471835C (en) 2003-12-23 2009-03-25 默克公司 Anti-hypercholesterolemic compounds
SA04250427A (en) 2003-12-23 2005-12-03 استرازينيكا ايه بي Diphenylazetidone derivates
WO2005069900A2 (en) 2004-01-16 2005-08-04 Merck & Co., Inc. Npc1l1 (npc3) and methods of identifying ligands thereof
AU2006259646A1 (en) * 2005-06-15 2006-12-28 Merck Sharp & Dohme Corp. Anti-hypercholesterolemic compounds
UY29607A1 (en) 2005-06-20 2007-01-31 Astrazeneca Ab CHEMICAL COMPOUNDS
SA06270191B1 (en) 2005-06-22 2010-03-29 استرازينيكا ايه بي Novel 2-Azetidinone Derivatives as Cholesterol Absorption Inhibitors for the Treatment of Hyperlipidaemic Conditions
AR057072A1 (en) 2005-06-22 2007-11-14 Astrazeneca Ab CHEMICAL COMPOUNDS DERIVED FROM 2-AZETIDINONE, PHARMACEUTICAL FORMULATION AND A COMPOUND PREPARATION PROCESS
DE102005055726A1 (en) * 2005-11-23 2007-08-30 Sanofi-Aventis Deutschland Gmbh Hydroxy-substituted diphenylazetidinones, processes for their preparation, medicaments containing these compounds and their use
US7910698B2 (en) 2006-02-24 2011-03-22 Schering Corporation NPC1L1 orthologues
TW200811098A (en) 2006-04-27 2008-03-01 Astrazeneca Ab Chemical compounds
EP2173893A4 (en) * 2007-06-28 2010-07-21 Merck Sharp & Dohme Use of mdck cells in the evaluation of cholesterol modulators
CN101580871B (en) * 2008-05-13 2013-06-05 中国科学院上海生命科学研究院 Method for screening new drug for lowering cholesterol based on analysis of change of NPC1L1 protein subcellular localization
US8609098B2 (en) * 2010-06-10 2013-12-17 Adbiotech Co., Ltd. Composition for repression of hyperlipidemia and obesity through suppression of intestinal cholesterol absorption
US10377815B2 (en) 2015-05-05 2019-08-13 Albert Einstein College Of Medicine Bispecific antibodies and fusion proteins that bind to EBOV and NPC1

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040132058A1 (en) * 2002-07-19 2004-07-08 Schering Corporation NPC1L1 (NPC3) and methods of use thereof
US20040161838A1 (en) * 2002-07-19 2004-08-19 Schering Corporation NPC1L1 (NPC3) and methods of use thereof

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5688787A (en) * 1991-07-23 1997-11-18 Schering Corporation Substituted β-lactam compounds useful as hypochlesterolemic agents and processes for the preparation thereof
US5561227A (en) * 1991-07-23 1996-10-01 Schering Corporation Process for the stereospecific synthesis of azetidinones
ATE158789T1 (en) * 1991-07-23 1997-10-15 Schering Corp SUBSTITUTED BETA-LACTAM COMPOUNDS AS HYPOCHOLESTEROLEMIC AGENTS AND METHOD FOR THE PRODUCTION THEREOF
US5688785A (en) * 1991-07-23 1997-11-18 Schering Corporation Substituted azetidinone compounds useful as hypocholesterolemic agents
LT3300B (en) * 1992-12-23 1995-06-26 Schering Corp Combination of a cholesterol biosynhtesis inhibitor and a beta- lactam cholesterol absorbtion inhibitor
LT3595B (en) * 1993-01-21 1995-12-27 Schering Corp Spirocycloalkyl-substituted azetidinones useful as hypocholesterolemic agents
KR0176001B1 (en) * 1993-07-09 1999-03-20 에릭 에스. 딕커 Process for the synthesis of azetidinones
US5631365A (en) * 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
US5627176A (en) * 1994-03-25 1997-05-06 Schering Corporation Substituted azetidinone compounds useful as hypocholesterolemic agents
US5633246A (en) * 1994-11-18 1997-05-27 Schering Corporation Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
US5624920A (en) * 1994-11-18 1997-04-29 Schering Corporation Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
US5656624A (en) * 1994-12-21 1997-08-12 Schering Corporation 4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents
US5618707A (en) * 1996-01-04 1997-04-08 Schering Corporation Stereoselective microbial reduction of 5-fluorophenyl-5-oxo-pentanoic acid and a phenyloxazolidinone condensation product thereof
WO1997016424A1 (en) * 1995-11-02 1997-05-09 Schering Corporation Process for preparing 1-(4-fluorophenyl)-3(r)-(3(s)-hydroxy-3-([phenyl or 4-fluorophenyl])-propyl)-4(s)-(4-hydroxyphenyl)-2-azetidinone
US5739321A (en) * 1996-05-31 1998-04-14 Schering Corporation 3-hydroxy γ-lactone based enantionselective synthesis of azetidinones
US5886171A (en) * 1996-05-31 1999-03-23 Schering Corporation 3-hydroxy gamma-lactone based enantioselective synthesis of azetidinones
US5756470A (en) * 1996-10-29 1998-05-26 Schering Corporation Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
WO1999001555A1 (en) * 1997-07-03 1999-01-14 The United States Of America Represented By The Secretary, Department Of Health And Human Services Genes for niemann-pick type c disease
US6133001A (en) * 1998-02-23 2000-10-17 Schering Corporation Stereoselective microbial reduction for the preparation of 1-(4-fluorophenyl)-3(R)-[3(S)-Hydroxy-3-(4-fluorophenyl)propyl)]-4(S)-(4 -hydroxyphenyl)-2-azetidinone
US5919672A (en) * 1998-10-02 1999-07-06 Schering Corporation Resolution of trans-2-(alkoxycarbonylethyl)-lactams useful in the synthesis of 1-(4-fluoro-phenyl)-3(R)- (S)-hydroxy-3-(4-fluorophenyl)-propyl!-4(S)-(4-hydroxyphenyl)-2-azetidinone
ATE297892T1 (en) 1998-12-07 2005-07-15 Schering Corp METHOD FOR PRODUCING AZETIDINONES
US6207822B1 (en) * 1998-12-07 2001-03-27 Schering Corporation Process for the synthesis of azetidinones
CA2367289C (en) 1999-04-05 2008-02-12 Schering Corporation Stereoselective microbial reduction for the preparation of 1-(4-fluorophenyl)-3(r)-[3(s)-hydroxy-3-(4-fluorophenyl)propyl)]-4(s)-(4-hydroxyphenyl)-2-azetidinone
AU4343500A (en) * 1999-04-16 2000-11-02 Schering Corporation Use of azetidinone compounds
EP1572987A4 (en) 2000-02-03 2005-11-30 Nuvelo Inc Novel nucleic acids and polypeptides
AU2001242750A1 (en) 2000-03-24 2001-10-03 Takeda Chemical Industries Ltd. Novel protein, process for producing the same and use thereof
US6436703B1 (en) 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
RS51449B (en) * 2001-01-26 2011-04-30 Schering Corporation Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
ATE305459T1 (en) 2001-03-28 2005-10-15 Schering Corp METHOD FOR THE ENANTIOSELECTIVE SYNTHESIS OF AZETIDINONE INTERMEDIATE PRODUCTS
AU2003239706A1 (en) 2002-05-23 2003-12-12 Devgen Nv Method for determining the influence of a compound on cholesterol transport
US20040093629A1 (en) * 2002-07-19 2004-05-13 Schering Corporation NPC1L1 (NPC3) and methods of use thereof
US20040137467A1 (en) * 2002-07-19 2004-07-15 Schering Corporation NPC1L1 (NPC3) and methods of use thereof
WO2004014947A1 (en) 2002-08-06 2004-02-19 Aventis Pharma Deutschland Gmbh Method for isolating an intestinal cholesterol binding protein
CA2501685A1 (en) 2002-10-08 2004-04-22 Massachusetts Institute Of Technology Compounds for modulation of cholesterol transport
WO2005069900A2 (en) 2004-01-16 2005-08-04 Merck & Co., Inc. Npc1l1 (npc3) and methods of identifying ligands thereof
CA2579790A1 (en) 2004-07-30 2006-02-09 Mount Sinai School Of Medicine Of New York University Npc1l1 and npc1l1 inhibitors and methods of use thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040132058A1 (en) * 2002-07-19 2004-07-08 Schering Corporation NPC1L1 (NPC3) and methods of use thereof
US20040161838A1 (en) * 2002-07-19 2004-08-19 Schering Corporation NPC1L1 (NPC3) and methods of use thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1723414A4 *

Also Published As

Publication number Publication date
JP2007526998A (en) 2007-09-20
CA2553769C (en) 2011-01-04
CA2553769A1 (en) 2005-08-04
WO2005069900B1 (en) 2006-08-03
US20100009461A1 (en) 2010-01-14
EP1723414A2 (en) 2006-11-22
MXPA06008124A (en) 2007-01-26
EP1723414A4 (en) 2008-03-26
JP4590417B2 (en) 2010-12-01
US7901893B2 (en) 2011-03-08
WO2005069900A2 (en) 2005-08-04

Similar Documents

Publication Publication Date Title
WO2005069900A3 (en) Npc1l1 (npc3) and methods of identifying ligands thereof
WO2004064972A3 (en) Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions
WO2006016960A3 (en) Method for purifying a protein of the cystine-knot superfamily
WO2007008917A3 (en) Modulation of protein functionalities
EA200702210A1 (en) METHOD FOR CLEANING PROTEINS
WO2006023831A3 (en) Sequential protein isolation and purification schemes by affinity chromatography
EP1927584A4 (en) Carrier for separation, method for separation of compound, and method for synthesis of peptide using the carrier
WO2006044078A3 (en) Apparatus and method for analysis of molecules
IL196902A0 (en) Collections of capture compounds, and methods for analyzing the proteome
WO2006078859A3 (en) Methods for separating compounds
WO2011146179A3 (en) Apparatus and process of purification of proteins
ZA200710330B (en) Methods of purifying FC region containing proteins
ATE445642T1 (en) SEPARATION OF POLYPEPTIDES USING A RACEMIZED AMINO ACID
WO2004074310A8 (en) Mycobacterial diagnostics
DE602006019111D1 (en) PROCESS FOR ISOLATING ANALYTES FROM A SAMPLE
WO2004078938A3 (en) Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
ATE408624T1 (en) METHOD FOR PURIFYING FSH
DE502004011957D1 (en) NEW CYANOPYRROLIDIDES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS MEDICAMENTS
WO2003078600A3 (en) Human monoclonal antibodies to influenza m2 protein and methods of making and using same
WO2009037297A3 (en) Method for the preparation of new oligoclonal antibodies
WO2004035742A3 (en) Sets of digital antibodies directed against short epitopes, and methods using same
PL1960427T3 (en) Multimeric fc receptor polypeptides
EP1811016A4 (en) Membrane filter for microbe detection
WO2006046134A3 (en) Method of screening by using conformation sensitive peptides
WO2006108051A3 (en) Compositions and methods relating to alzheimer's disease

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2006549676

Country of ref document: JP

Ref document number: PA/a/2006/008124

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2553769

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

WWE Wipo information: entry into national phase

Ref document number: 2005711542

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2005711542

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10586310

Country of ref document: US